Guolo F, et al. Blood Cancer J. 2020: Treatment with Vyxeos Liposomal in a compassionate use program

Discover the full outcomes of this multicentre cohort in Italy, where 71 patients were treated with Vyxeos Liposomal showing a 12-month OS of 68.6% and a manageable adverse events profile.1

Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Safety Vyxeos Liposomal Data


Adverse events should be reported. Reporting forms and information for the UK can be found at

For Ireland, reporting forms and information can be found at:

Adverse events should also be reported to Jazz Pharmaceuticals at

UK-VYX-2100175 | September 2021